STOCK TITAN

[Form 4] Progyny, Inc. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Progyny director and Chief Executive Officer Peter Anevski reported an insider transaction dated 10/01/2025. The Form 4 shows 7,977 shares of Progyny common stock were disposed of at a price of $21.52 per share, with the filer retaining beneficial ownership of 539,564 shares following the transaction. The filing explains the sale resulted from shares withheld to cover taxes on vested restricted stock units and notes the remaining reportable shares are held directly by PECO ANEVSKI 2020 SD LLC. The Form 4 was signed by an attorney-in-fact on 10/02/2025.

Il direttore di Progyny e Amministratore Delegato Peter Anevski ha riferito un'operazione interna datata 10/01/2025. Il modulo 4 mostra che sono stati disfatti 7.977 azioni ordinarie di Progyny a un prezzo di $21.52 per azione, con il dichiarante che mantiene la proprietà vantaggiosa di 539.564 azioni dopo l'operazione. La dichiarazione spiega che la vendita è derivata da azioni trattenute per coprire le tasse sui restricted stock units maturati e segnala che le restanti azioni segnalate sono detenute direttamente da PECO ANEVSKI 2020 SD LLC. Il modulo 4 è stato firmato da un procuratore-in-fatto il 10/02/2025.

El director de Progyny y Director Ejecutivo Peter Anevski informó sobre una transacción interna fechada el 10/01/2025. El Formulario 4 muestra que se deshicieron 7.977 acciones ordinarias de Progyny a un precio de $21.52 por acción, manteniéndose la titularidad beneficiosa de 539.564 acciones tras la operación. La presentación explica que la venta se debió a acciones retenidas para cubrir impuestos sobre unidades de acciones restringidas vestidas y señala que las acciones reportables restantes están detentadas directamente por PECO ANEVSKI 2020 SD LLC. El Formulario 4 fue firmado por un apoderado el 10/02/2025.

Progyny의 이사이자 최고경영자 Peter Anevski가 일정한 내부거래를 보고했습니다. 날짜는 2025년 10월 1일로 되어 있습니다. Form 4에는 Progyny 보통주가 7,977주가 $21.52의 가격으로 처분되었으며, 거래 후 피고인은 539,564주를 직접 보유하고 있는 것으로 기재되어 있습니다. 제출서에는 매도는 취득한 주식의 세금을 충당하기 위해 보유한 주식 때문이라고 설명되며, 남은 보고 대상 주식은 PECO ANEVSKI 2020 SD LLC가 직접 보유하고 있다고 명시되어 있습니다. Form 4는 2025년 10월 2일에 대리인에 의해 서명되었습니다.

Le directeur de Progyny et PDG Peter Anevski a rapporté une transaction interne datée du 10/01/2025. Le formulaire 4 indique que 7 977 actions ordinaires de Progyny ont été cédées au prix de $21,52 par action, le titulaire conservant la propriété bénéficiaire de 539 564 actions après la transaction. Le dépôt explique que la vente résulte d’actions retenues pour couvrir les impôts sur les unités d’action restreintes acquises et note que les actions reportables restantes sont détenues directement par PECO ANEVSKI 2020 SD LLC. Le formulaire 4 a été signé par un mandataire le 02/10/2025.

Progyny-Direktor und Chief Executive Officer Peter Anevski meldete eine Insider-Transaktion vom 10/01/2025. Das Formular 4 zeigt, dass 7.977 Stammaktien von Progyny zum Preis von $21,52 pro Aktie veräußert wurden, wobei der Meldende nach der Transaktion weiterhin Eigentum an 539.564 Aktien hält. Die Einreichung erklärt, dass der Verkauf darauf zurückzuführen ist, Aktien zurückzuhalten, um Steuern auf vestete Restricted Stock Units zu decken, und vermerkt, dass die verbleibenden meldepflichtigen Aktien direkt von PECO ANEVSKI 2020 SD LLC gehalten werden. Das Formular 4 wurde am 02/10/2025 von einem Bevollmächtigten unterzeichnet.

أعلن مدير Progyny والرئيس التنفيذي Peter Anevski عن صفقة داخلية بتاريخ 01/10/2025. يظهر النموذج 4 7,977 أسهم عادية من Progyny بيعت بسعر $21.52 للسهم، مع احتفاظ العارض بملكية فاعلة قدرها 539,564 سهمًا بعد الصفقة. توضح الإيداع أن البيع نتج عن أسهم حُجزت لتغطية الضرائب على وحدات الأسهم المقيدة الممنوحة، وتذكر أن الأسهم القابلة للإبلاغ المتبقية مملوكة مباشرة من قبل PECO ANEVSKI 2020 SD LLC. تم توقيع النموذج 4 من قبل وكيل مفوض في 10/02/2025.

Progyny 董事长及首席执行官 Peter Anevski 报告了一笔内部交易,日期为 10/01/2025。 Form 4 显示以每股 $21.52 的价格处置了 7,977 股 Progyny 普通股,交易后申报人仍持有 539,564 股的受益所有权。申报解释称,此次出售是因为扣留股份以支付已归属受限股票单位的税款,并指出剩余的可报告股票由 PECO ANEVSKI 2020 SD LLC 直接持有。Form 4 由一名代理人在 10/02/2025 签署。

Positive
  • Retains 539,564 shares of Progyny common stock after the transaction, indicating continued substantial ownership
  • Sale attributed to tax withholding on vested RSUs, a routine administrative reason rather than a discretionary cash raise
Negative
  • 7,977 shares disposed at $21.52 on 10/01/2025, representing an insider sale reported by the CEO

Insights

TL;DR: CEO sold 7,977 shares at $21.52; retains 539,564 shares, sale tied to tax withholding.

The Form 4 records a disposition of 7,977 shares on 10/01/2025 executed under a vesting tax-withholding event rather than a market-driven decision. Such withholdings are common when restricted stock units vest and do not necessarily indicate a change in management view.

The reporting also clarifies ownership structure: reportable shares are held directly by PECO ANEVSKI 2020 SD LLC, which is relevant for assessing control and potential future filings. The signature by an attorney-in-fact on 10/02/2025 completes the required disclosure.

Il direttore di Progyny e Amministratore Delegato Peter Anevski ha riferito un'operazione interna datata 10/01/2025. Il modulo 4 mostra che sono stati disfatti 7.977 azioni ordinarie di Progyny a un prezzo di $21.52 per azione, con il dichiarante che mantiene la proprietà vantaggiosa di 539.564 azioni dopo l'operazione. La dichiarazione spiega che la vendita è derivata da azioni trattenute per coprire le tasse sui restricted stock units maturati e segnala che le restanti azioni segnalate sono detenute direttamente da PECO ANEVSKI 2020 SD LLC. Il modulo 4 è stato firmato da un procuratore-in-fatto il 10/02/2025.

El director de Progyny y Director Ejecutivo Peter Anevski informó sobre una transacción interna fechada el 10/01/2025. El Formulario 4 muestra que se deshicieron 7.977 acciones ordinarias de Progyny a un precio de $21.52 por acción, manteniéndose la titularidad beneficiosa de 539.564 acciones tras la operación. La presentación explica que la venta se debió a acciones retenidas para cubrir impuestos sobre unidades de acciones restringidas vestidas y señala que las acciones reportables restantes están detentadas directamente por PECO ANEVSKI 2020 SD LLC. El Formulario 4 fue firmado por un apoderado el 10/02/2025.

Progyny의 이사이자 최고경영자 Peter Anevski가 일정한 내부거래를 보고했습니다. 날짜는 2025년 10월 1일로 되어 있습니다. Form 4에는 Progyny 보통주가 7,977주가 $21.52의 가격으로 처분되었으며, 거래 후 피고인은 539,564주를 직접 보유하고 있는 것으로 기재되어 있습니다. 제출서에는 매도는 취득한 주식의 세금을 충당하기 위해 보유한 주식 때문이라고 설명되며, 남은 보고 대상 주식은 PECO ANEVSKI 2020 SD LLC가 직접 보유하고 있다고 명시되어 있습니다. Form 4는 2025년 10월 2일에 대리인에 의해 서명되었습니다.

Le directeur de Progyny et PDG Peter Anevski a rapporté une transaction interne datée du 10/01/2025. Le formulaire 4 indique que 7 977 actions ordinaires de Progyny ont été cédées au prix de $21,52 par action, le titulaire conservant la propriété bénéficiaire de 539 564 actions après la transaction. Le dépôt explique que la vente résulte d’actions retenues pour couvrir les impôts sur les unités d’action restreintes acquises et note que les actions reportables restantes sont détenues directement par PECO ANEVSKI 2020 SD LLC. Le formulaire 4 a été signé par un mandataire le 02/10/2025.

Progyny-Direktor und Chief Executive Officer Peter Anevski meldete eine Insider-Transaktion vom 10/01/2025. Das Formular 4 zeigt, dass 7.977 Stammaktien von Progyny zum Preis von $21,52 pro Aktie veräußert wurden, wobei der Meldende nach der Transaktion weiterhin Eigentum an 539.564 Aktien hält. Die Einreichung erklärt, dass der Verkauf darauf zurückzuführen ist, Aktien zurückzuhalten, um Steuern auf vestete Restricted Stock Units zu decken, und vermerkt, dass die verbleibenden meldepflichtigen Aktien direkt von PECO ANEVSKI 2020 SD LLC gehalten werden. Das Formular 4 wurde am 02/10/2025 von einem Bevollmächtigten unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Anevski Peter

(Last) (First) (Middle)
C/O PROGYNY, INC.
1359 BROADWAY, 2ND FLOOR

(Street)
NEW YORK NY 10018

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Progyny, Inc. [ PGNY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF EXECUTIVE OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 F(1) 7,977 D $21.52 539,564 D
Common Stock 1 I See footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares withheld for payment of withholding taxes upon the vesting of restricted stock units granted to the Reporting Person.
2. The reportable securities are held directly by the PECO ANEVSKI 2020 SD LLC.
Remarks:
/s/ Mark Livingston, Attorney-in-Fact 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Progyny insider Peter Anevski report on Form 4 (PGNY)?

The Form 4 reports a disposition of 7,977 shares at $21.52 per share on 10/01/2025, with beneficial ownership of 539,564 shares remaining.

Why were the shares sold according to the Form 4?

The filing states the shares were withheld to cover payment of withholding taxes upon the vesting of restricted stock units granted to the reporting person.

Who holds the reportable securities for Anevski?

The reportable securities are held directly by PECO ANEVSKI 2020 SD LLC as disclosed in the Form 4.

When was the Form 4 signed and filed?

The Form 4 was signed by an attorney-in-fact on 10/02/2025 and reports the transaction dated 10/01/2025.

Does the Form 4 indicate any new derivative positions?

No. The filing lists only non-derivative common stock transactions and contains no new derivative securities.
Progyny, Inc.

NASDAQ:PGNY

PGNY Rankings

PGNY Latest News

PGNY Latest SEC Filings

PGNY Stock Data

1.77B
79.47M
7.58%
103.87%
8.08%
Healthcare Plans
Services-misc Health & Allied Services, Nec
Link
United States
NEW YORK